ANTI-14-3-3ETA MULTIPLEX
Anti-14-3-3eta Multiplex is a first-in-class biomarker test for Axial Spondyloarthritis.
What is Axial Spondyloarthritis?
Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac joints, causing pain, stiffness and joint damage.
Burden of Diagnostic Delay
AxSpA imposes a significant burden on patients, impacting physical function, mental health, and work productivity. Diagnosis is often delayed by 7-10 years due to the absence of reliable biomarkers, with many cases misdiagnosed as chronic low back pain. Early detection is critical for preventing long-term damage and improving patient outcomes.1
Average years diagnostic delay
Had trouble getting out of bed
Were affected by some form of psychological distress
Reported difficulty finding a job due to their disease
Anti-14-3-3eta Multiplex addresses critical gaps in patient care to improve outcomes
Streamlined Diagnostic Process
Aids in the early and accurate diagnosis of axSpA, reducing the 7-10 year average time to diagnosis.
Complementary to Imaging
Offers diagnostic support alongside traditional imaging.
Clinical Confidence
Enables evidence based decisions, leading to more timely and appropriate treatment plans.
Improved Outcomes
Anti-14-3-eta Multiplex aids in earlier detection and intervention of axSpA, potentially preventing long-term spinal damage.
Anti-14-3-3eta Multiplex is highly sensitive and specific for early diagnosis of axSpa
Early and Accurate Diagnosis
Anti-14-3-3eta Multiplex is highly sensitive (76%) and highly specific (74%) to enable differentiation between axSpA and chronic low back pain.3
Complementary to CRP
Combined with CRP, the test can identify 90% of axSpA patients, improving diagnostic accuracy.4
HLA-B27 Independent
Provides diagnostic value even in patients who are negative for traditional markers like HLA-B27.4
Early and Accurate Diagnosis
Anti-14-3-3eta Multiplex is highly sensitive (76%) and highly specific (74%) to enable differentiation between axSpA and chronic low back pain.3
Anti-14-3-3eta Multiplex is highly sensitive and highly specific for early diagnosis of axSpA
Anti-14-3-3eta Multiplex is now available for early access in Knoxville, Tennessee, through our partnership with New Day Diagnostics as a laboratory-developed test (LDT).
Anti-14-3-3eta Multiplex is the only diagnostic test for axSpA
Anti-14-3-3eta Multiplex is a novel diagnostic test that detects autoantibodies against the normally intracellular 14-3-3eta protein, a well-established biomarker in autoimmune rheumatologic disorders.
References:
- Poddubnyy D, Garrido-Cumbrera M, Sommerfleck F, et al. POS0689. Diagnostic delay in patients included in the International Map of Axial Spondyloarthritis: associations with geographic, socio-demographic and disease-related factors. Annals of the Rheumatic Diseases. 2023;82:628-629
- The burden of axial spondyloarthritis: A global patient perspective. International Map of Axial Spondyloarthritis (IMAS) Report. 2024, Jan. https://asif.info/imas/imas-global-report
- Marotta A, Maksymowych WP, Wichuk S, Sidhu N. P54 Novel Diagnostic 14-3-3η Auto-Antibody Marker for Axial Spondyloarthritis: A Longitudinal Study. Fourteenth International Congress on Spondyloarthritides. Clin Exp Rheumatol. 2024.
- Marotta A, Maksymowych WP, Wichuk S, Sidhu N. POS1094 Autoantibodies to 14-3-3η in Axial Spondyloarthritis. Annals of the Rheumatic Diseases. 2024;83:892-893.